Logo

American Heart Association

  9
  0


Final ID: MDP1174

Feasibility and Outcomes of Using an Intraprocedural Artificial Intelligence System in Recognizing Regions of Dispersion and Generating Sequential Maps to Assist in Radiofrequency Ablations for Persistent Atrial Fibrillation

Abstract Body (Do not enter title and authors here): Background:
Pulmonary vein isolation (PVI) is the cornerstone therapy during catheter ablation of atrial fibrillation (AF) isolation. 30% of patients continue to have recurrent AF despite pulmonary vein (PV) isolation. Defining targets for catheter ablation in PV non responder subgroup continues to be challenging despite technological advances. Volta AF-Xplorer™ (VX) is an artificial intelligence (AI) system that analyzes intracardiac signals using electrocardiograms to recognize regions of spatial temporal dispersion and generate sequential maps as targets for ablation.
Objective:
We aim to assess the clinical feasibility and outcomes of the VX AI mapping algorithm during RF catheter ablations to treat recurrent persistent AF in PV non responders.
Methods:
A single center prospective analysis of patients undergoing repeat ablation for recurrent persistent AF using VX mapping software was performed. All patients had previous PVIs, with recurrence of AF and failed at least 2 antiarrhythmic drugs. Patients underwent 3D mapping using Carto and Ensite X mapping systems with real time detection and annotation of spatial temporal dispersion using the Volta technology. The identified targets were ablated until endpoints of termination and non inducibility was achieved and intraprocedural data points were recorded.
Results:
19 patients with a mean age of 67±10.15 years 63.2% male were included in this analysis. Average total procedure time was 68±33 min and average mapping time was 17±10 min. Ablations were performed under zero fluoroscopy. PVI was confirmed in all cases. Ablation was performed at dispersion points identified using the AI mapping system. Termination was achieved in 18 out of the 19 cases (94.7%). 16 patients converted directly to normal sinus rhythm (NSR) and 2 patients to atrial flutter and then to NSR. The one patient that did not terminate required cardioversion but was not inducible with pacing maneuvers.
Conclusion:
This experience highlights the clinical safety, utility, feasibility, and outcomes of the Volta AF-Xplorer AI mapping software during catheter ablation of PV non responders for recurrent persistent AF.
  • Gabrah, Kirollos  ( Arrhythmia Research Group , State University , Arkansas , United States )
  • Doty, Brandon  ( Arrhythmia Research Group , State University , Arkansas , United States )
  • Cain, Jonathan  ( Arrhythmia Research Group , State University , Arkansas , United States )
  • Maldonado, Noel  ( Arrhythmia Research Group , State University , Arkansas , United States )
  • Lee, Bridget  ( Arrhythmia Research Group , State University , Arkansas , United States )
  • Mahtani, Arun  ( Arrhythmia Research Group , State University , Arkansas , United States )
  • Brider, Jamarcus  ( Arrhythmia Research Group , State University , Arkansas , United States )
  • Al-hindi, Feross  ( Arrhythmia Research Group , State University , Arkansas , United States )
  • Nair, Devi  ( Arrhythmia Research Group , State University , Arkansas , United States )
  • Author Disclosures:
    Kirollos Gabrah: DO NOT have relevant financial relationships | Brandon Doty: DO NOT have relevant financial relationships | Jonathan Cain: DO NOT have relevant financial relationships | Noel Maldonado: DO NOT have relevant financial relationships | Bridget Lee: DO NOT have relevant financial relationships | Arun Mahtani: DO NOT have relevant financial relationships | Jamarcus Brider: DO NOT have relevant financial relationships | Feross Al-Hindi: DO NOT have relevant financial relationships | Devi Nair: DO have relevant financial relationships ; Consultant:Medtronic :Active (exists now) ; Research Funding (PI or named investigator):Abbott:Active (exists now) ; Advisor:Abbott:Active (exists now) ; Consultant:Abbott:Active (exists now) ; Research Funding (PI or named investigator):Biosense Webster:Active (exists now) ; Advisor:Biosense Webster:Active (exists now) ; Consultant:Biosense Websterr:Active (exists now) ; Research Funding (PI or named investigator):Boston Scientific:Active (exists now) ; Advisor:Boston Scientific:Active (exists now) ; Consultant:Boston Scientific :Active (exists now) ; Research Funding (PI or named investigator):Medtronic:Active (exists now) ; Advisor:Medtronic:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Wave of the Future: Artificial Intelligence & Atrial fibrillation Before, During and After the EP Lab

Sunday, 11/17/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
Ablation versus Anti-arrhythmic Drug Therapy for Ventricular Tachycardia in Patients with Ischemic Heart Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Khan Ubaid, Chaudhry Kashif, Amin Ahmed Mazen, A. Ibrahim Ahmed, Imran Muhammad, Rakab Mohamed, Iltaf Arej, M. Albarakat Majd, Ranabhat Chet, Brilliant Justin

Adverse Events with Pulsed Field Ablation - A Review of the Food and Drug Administration’s Manufacturer and User Facility Device Experience Database

Cooper Julie, Zagrodzky William, Zagrodzky Jason, Omotoye Samuel, Sardana Mayank, Kaplan Andrew, Link Mark, Bunch Thomas, Daniels James

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available